Novo Nordisk GLP-1 sales diverge
Novo Nordisk's oral GLP-1 sales patterns differ from injectables, impacting revenue. This may affect the company's market share in the diabetes treatment space.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.